Overview

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended dose of lenalidomide in subjects with relapse and refractory Waldenstrom Macroglobulinemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital, Lille
Collaborator:
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide